Gold prices have fallen below the key $4,000-an-ounce level due to persistent inflation and expectations that the Federal Reserve will continue raising interest rates. After holding support around $4,000 for two weeks, gold dropped to $3,987 an ounce, pressured by a stronger U.S. dollar and rising Treasury yields. Analysts warn that if gold sustains below this level, it could trigger further selling, with potential targets near $3,900 and lower. While central bank gold purchases remain strong, weakening investment demand and reduced safe-haven appeal amid easing geopolitical tensions add to the downside risks. Investors will watch upcoming Fed decisions closely for clues on gold's direction.
Gold prices provide context for readers, with Pluang market data as of Nov 12, 2026 03:31 WIB. Among 150 US stocks priced on Pluang, 96 rose and 52 fell. Notable movers include AMAT at USD 395.49 (+6.16%), FCEL at USD 10.88 (+5.79%), and HPE at USD 50.51 (+5.31%), with varied Pluang order activity and typical hold times.
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
Shurgard Self Storage, a leading European self-storage REIT, is currently trading at a significant discount to its net tangible assets (NTA) with a valuation of 0.48x NTA. It offers an attractive dividend yield of 4.5% and benefits from strong urbani...
Kiniksa Pharmaceuticals International, plc announced that its management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 16, 2026. The event will be webcast live and available for replay on the ...
Lakefront Biotherapeutics reported a net profit of €13.9 million for the first nine months of 2026, a significant turnaround from a €461.3 million loss in the same period last year. The company highlighted progress with its autoimmune drug gamgertami...
